Akrevia Therapeutics is discovering and developing the next generation of cancer immunotherapies, offering the promise of safer, more efficacious therapeutics Akrevia Therapeutics, is a privately-held biopharmaceutical company focused on developing highly-potent, targeted immuno-oncology therapeutics.
Akrevia Therapeutics, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/akrevia” connections=”true” suffix=””]
Akrevias proprietary Aklusion_ platform, based on technology licensed from City of Hope and Thomas Jefferson University, allows potently active biological molecules to be inactive until they encounter the tumor microenvironment. By tailoring pharmacokinetic and pharmacodynamic properties in parallel, Aklusion allows design of molecules with potential best-in-class potency and selectivity.
In Sep 2018, Akrevia Therapeutics, raised $30 Mn in Series A financing, led by F-Prime Capital Partners and Atlas Venture.